Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

VEGFR Therapy’s Role in Reducing RCC Progression

Curr Med Res Opin; ePub 2018 Feb 1; Tannir, et al

With checkpoint inhibitors emerging as potential treatment approaches for advanced renal cell carcinoma, combining or sequencing them with vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKIs) may reduce or delay disease progression, according to a recent review. Preliminary evidence suggests that VEGFR-TKIs can reverse immunosuppressive effects in the tumor microenvironment, potentially enhancing the effects of subsequent immunotherapy with checkpoint inhibitors. The authors discuss the potential role of first-line VEGFR-TKIs in priming the tumor microenvironment for immunotherapy.

Citation:

Tannir N, Hammers H, Amin A. Impact of comorbidities on functional recovery from partial nephrectomy. [Published online ahead of print February 1, 2018]. Curr Med Res Opin. doi:10.1080/03007995.2018.1423960.

This Week's Must Reads

Overall survival factor in metastatic ccRCC, Thiery-Vuillemin A et al. Clinical Genitourinary Cancer 2018; 16: e297-e305

High perirenal fat thickness predicts poor progression-free survival in patients with localized ccRCC, Huang H et al. Urologic Oncology: Seminars and Original Investigations 2018; 36: 157.e1-157.e6

AXL linked to worse outcome of metastatic RCCs treated with sunitinib, Zucca L E et al. Urologic Oncology: Seminars and Original Investigations 2018: 36; 11.e13-11.e21

Pathologic predictors in lymph node dissection of metastatic RCC, Chipollini J et al. Clinical Genitourinary Cancer 2018; 16: Pages e443-450.

Plated-lymphocyte ratio is correlated with poor prognosis in RCC, Wang Z et al. Clinica Chimica Acta; 2018; 480: 166-72.

Must Reads in Renal Cell Carcinoma

Overall survival factor in metastatic ccRCC, Thiery-Vuillemin A et al. Clinical Genitourinary Cancer 2018; 16: e297-e305

High perirenal fat thickness predicts poor progression-free survival in patients with localized ccRCC, Huang H et al. Urologic Oncology: Seminars and Original Investigations 2018; 36: 157.e1-157.e6

AXL linked to worse outcome of metastatic RCCs treated with sunitinib, Zucca L E et al. Urologic Oncology: Seminars and Original Investigations 2018: 36; 11.e13-11.e21

Pathologic predictors in lymph node dissection of metastatic RCC, Chipollini J et al. Clinical Genitourinary Cancer 2018; 16: Pages e443-450.

Plated-lymphocyte ratio is correlated with poor prognosis in RCC, Wang Z et al. Clinica Chimica Acta; 2018; 480: 166-72.